International Stem Cell (International Stem Cell) EPS (Basic) : $-0.06 (TTM As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell EPS (Basic)?

International Stem Cell's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.06.

International Stem Cell's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.06.

International Stem Cell's EPS without NRI for the three months ended in Mar. 2024 was $-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.06.

During the past 3 years, the average EPS without NRI Growth Rate was 35.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 39.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 39.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, International Stem Cell's highest 3-Year average EPS without NRI Growth Rate was 62.80% per year. The lowest was -46.20% per year. And the median was 27.10% per year.

International Stem Cell EPS (Basic) Historical Data

The historical data trend for International Stem Cell's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell EPS (Basic) Chart

International Stem Cell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.57

-0.36

-0.11

-0.04

-0.02

International Stem Cell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-	0.03	-0.02	-0.04	-0.03

International Stem Cell EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

International Stem Cell's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.131	-	0)	/	8.004
	=	-0.02

International Stem Cell's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.214	-	0)	/	8.004
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

International Stem Cell (OTCPK:ISCO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

International Stem Cell EPS (Basic) Related Terms

Thank you for viewing the detailed overview of International Stem Cell's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

International Stem Cell (International Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website

https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

Executives

Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin	10 percent owner	1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova	officer: Dir. of Legal Affairs & Oper.	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don	director	2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens	officer: Acting Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi	officer: Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin	director, 10 percent owner	2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak	officer: Interim CFO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw	officer: Executive Vice President	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund	director	C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc	10 percent owner	5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May	officer: President and COO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen	officer: Chief Financial Officer	5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus	director, officer: President	2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027